GTS Securities’s BioMarin Pharmaceuticals BMRN Stock Holding History

GTS Securities’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-34,440	Closed	-$2.42M	–	1599
2024 Q3	$2.42M	Buy	34,440 +12,221	+55%	+$1.02M	0.01%	1437
2024 Q2	$1.83M	Buy	22,219 +8,987	+68%	+$748K	﹤0.01%	1571
2024 Q1	$1.16M	Sell	13,232 -13,661	-51%	-$1.22M	﹤0.01%	1886
2023 Q4	$2.59M	Buy	26,893 +15,039	+127%	+$1.33M	﹤0.01%	1467
2023 Q3	$1.05M	Buy	11,854 +6,759	+133%	+$601K	﹤0.01%	1976
2023 Q2	$442K	Buy	+5,095	New	+$479K	0.01%	711

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

GTS Securities's BMRN Position: Q4 2024 in Review

GTS Securities sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2024, closing a stake of 34,440 shares — an estimated $2.42M sold.

GTS Securities first reported a position in BMRN in Q2 2023 and held it in 6 quarters. The position peaked at $2.59M in Q4 2023. 543 funds tracked by Wall St. Rank hold BMRN as of Q4 2024.

GTS Securities reported no remaining BioMarin Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
GTS Securities sold 34,440 BioMarin Pharmaceuticals shares in Q4 2024, an estimated $2.42M.
GTS Securities first reported a position in BioMarin Pharmaceuticals in Q2 2023 and held it in 6 quarters.
GTS Securities's BioMarin Pharmaceuticals position peaked at $2.59M in Q4 2023.
543 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2024.

Based on GTS Securities's 13F filing for Q4 2024, filed 18 Feb 2025.